Side 1 fra 31 resultater
FIELD OF THE INVENTION
The invention relates to the regulation of human serine/threonine kinase.
BACKGROUND OF THE INVENTION
Intercellular signaling regulates a variety of important biological functions. For example, transforming growth factor type beta (TGF-.beta.) regulates the proliferation and
FIELD OF THE INVENTION
The field of the invention is anti-inflammatory agents.
BACKGROUND OF THE INVENTION
Biological Activity And Use Of Boron Compounds
Boron compounds are known to show a variety of different biological activities. Very often, boron compounds show enzyme inhibitory activity, and
FIELD OF THE INVENTION
Non-peptidic compounds are described for treatment of autoimmune diseases. Of particular interest are pipecolic acid derivatives compounds incorporating a characterizing segment condensed from pipecolic acid, aspartic acid, proline and threonine, or derivatives thereof, which
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 National Phase Entry of International Patent Application No. PCT/EP2016/067090 filed on Jul. 18, 2016 which claims benefit under 35 U.S.C. .sctn. 119(b) of EP Application No. 15177013.8 filed Jul. 16, 2015 and EP Application No.
TECHNICAL FIELD
The present invention relates to an agent for treating or preventing an inflammatory bowel disease, comprising a particular amino acid(s). The present invention also relates to an agent for inhibiting TNF production, comprising a particular amino acid(s).
BACKGROUND ART
An
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to compounds that inhibit serine/threonine kinases and are useful for treating hyperproliferative and neoplastic diseases by inhibiting signal transduction pathways, which are commonly overactive or overexpressed in
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds that inhibit serine/threonine kinases and are useful for treating hyperproliferative and neoplastic diseases by inhibiting signal transduction pathways, which are commonly overactive or overexpressed in
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to compounds that inhibit serine/threonine kinases and are useful for treating hyperproliferative and neoplastic diseases by inhibiting signal transduction pathways, which are commonly overactive or overexpressed in
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds that inhibit serine/threonine kinases and are useful for treating hyperproliferative and neoplastic diseases by inhibiting signal transduction pathways, which are commonly overactive or overexpressed in
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds that inhibit serine/threonine kinases and are useful for treating hyperproliferative and neoplastic diseases by inhibiting signal transduction pathways, which are commonly overactive or overexpressed in
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage application of co-pending PCT application PCT/GB2007/004114 filed Oct. 29, 2007, which claims the benefit of Great Britain application number 0621720.2 filed Nov. 1, 2006 and Great Britain application number 0715470.1 filed
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage application of co-pending PCT application PCT/GB2007/004117 filed Oct. 29, 2007, which claims the benefit of Great Britain application number 0621720.2 filed Nov. 1, 2006 and Great Britain application number 0715469.3 filed
The invention relates to Lysyl-Prolyl-Threonine lyophilized formulations, in particular to L-Lysyl-D-Prolyl-L-Threonine lyophilized formulations, that are stable in storage, and to a process for preparing the lyophilized formulations. Moreover, the invention relates to pharmaceutical and cosmetic
BACKGROUND OF THE INVENTION
This invention generally relates to methods for maintaining, improving or increasing the synthesis of mucins, especially in the gastrointestinal tract and lungs. The invention further relates to maintaining, improving or increasing the synthesis of mucins in a patient by
The present invention relates to substances which are useful in modifying cell--cell adhesion and in modifying the permeability of physiological barriers.
Cell--cell adhesion is of crucial importance for the development and maintenance of tissue structure. Furthermore, regulation of such adhesion